1Angrum AJ, Bakris GL. Angiotensin - converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.Semin Nephrol,2004.24:168
2Lewis EJ, Hunsicker LG, Clarke WR et al . Enoprotective effect of the angiotensin - receptor antagonist hbesaaan in patients with nephropathy due to type 2 diabetes. N Engl J Med,2001,345:851
3K/DOQI clinical practice guidelines for chronic kidney disease:Evaluation, classification,, and stratification. Kidney Disease Outcome Quality Initiative.AM J Kidney Dis,2002(suppl 2) :S1
6Chobanian AV, Barcris GL, Black HR et al . Seventh Report of the Joint National Committee On Prevention, Dectection, Evaluation, and Treatment of High Blood Pressure. Hypertension,2003,42:1 206
7Chobanian AV, Barcris GL, Black HR et al . Seventh Report of the Joint National Committee on Prevention, Dectection, Evaluation, and Treatment of High Blood Pressure: The JNC 7report. JAMA, 2003, 289:2 560
8Conlin PR, Chow DC, Miller ER Ⅲ et al . The effect of dietary patterna on blood pressure control in hypertension patient: Result from the Dietary Approaches to Stop Hypertension(DASH) Trail. Am J Hypertension, 2000,13:939
9Whelton SP,Chin A, Xin X et al .Effect of aerobic exercise on blood pressure:A meta- analysis of randomized, controlled trials:Ann Int Med,2002,136:493
10Sacks FM,Sverkey LP, Vollmer WM et al . Effects on blood Pressure of reduced Dietary Approaches to Stop Hypertension ( DASH ) diet. DASH-Sodium Collaborative Research Group. N Engl J Med,2001, 344:3
二级参考文献5
1Lewis EI, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med, 1993, 329:1456.
2Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet, 1998, 352:1252-1256.
3Burgess E. Conservative treatment to slow deterioration of renal function: evidence-based recommendations. Kidney Int,1999, 55Suppl 70: S17-S25.
4Mulrow PJ. Detection and control of hypertension in the population. The United States experience. Am J Hypertension, 1998, 11: 744-746.
4National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002,39(2 Suppl 1 ) : S1-266.
5Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension, 1987,9(2 Pt 2) : II 19- 26.
6Wanic-Kossowska M, Lehmann P, Czekalski S. Left ventricular hypertrophy in patients with chronic renal failure treated by hemodialysis. Pal Arch Med Wewn,2002,107(6) :539-546.
7Foley R N, Herzog C A , Collins A J. Blood pressure and long term mortality in United States haemodialysis patients: USRDS Waves 3 and 4 study [J]. Kidney Int, 2002, 62(5) : 1784 - 1790.
8Fagugli R M, Pasini P, Quintaliani G, et al. Association between extracellular water, pertension in haemodialysis Transplant, 2003, 18 ( 11 ) left ventricular mass and hypatients [ J ]. Nephrol Dial 2332 - 2338.
9Horl M P, Horl W H. Hemodialysis-associated hypertension: pathophysiology and therapy [J]. Am J Kidney Dis, 2002,39 : 227 - 244.
10Covic A, Mardare N G, Ardeleanu S, et al. Serial echocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation [ J ]. J Nephrol, 2006,19(6) : 783 - 793.
